Analysis of 587,826 adults with type 2 diabetes reveals significant disparities in SGLT2 inhibitor prescribing 18 months after updated guidelines. Heart failure patients achieved 29-31% uptake rates, while those with cardiovascular disease alone reached only 19.5%, despite equal clinical recommendations. The drugs showed concerning prescription gaps among older adults over 60, women, Black patients, and those in deprived areas. These findings highlight a critical implementation challenge for medications that reduce cardiovascular death risk by 10-40% according to network meta-analyses. SGLT2 inhibitors like empagliflozin and dapagliflozin represent paradigm-shifting diabetes treatments that protect hearts and kidneys beyond glucose control. The uneven adoption suggests thousands of high-risk patients remain undertreated despite strong evidence for cardiovascular protection. However, this preprint awaiting peer review examined observational prescription patterns rather than clinical outcomes, limiting causal interpretations. The persistent inequalities in access to these life-extending medications underscore the gap between evidence-based guidelines and real-world healthcare delivery, particularly affecting vulnerable populations who often face the highest cardiovascular risks.